KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Adaptive Biotechnologies (ADPT) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Adaptive Biotechnologies' Interest Expenses rose 108.88% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 116.84%. This contributed to the annual value of $11.6 million for FY2024, which is 1608.7% down from last year.
  • Adaptive Biotechnologies' Interest Expenses amounted to $3.0 million in Q3 2025, which was up 108.88% from $2.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Interest Expenses' 5-year high stood at $3.7 million during Q3 2023, with a 5-year trough of $653000.0 in Q3 2022.
  • Its 4-year average for Interest Expenses is $3.0 million, with a median of $3.0 million in 2025.
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 45926.49% in 2023, then crashed by 2521.5% in 2024.
  • Quarter analysis of 4 years shows Adaptive Biotechnologies' Interest Expenses stood at $3.6 million in 2022, then fell by 15.98% to $3.0 million in 2023, then decreased by 1.99% to $3.0 million in 2024, then grew by 0.64% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.9 million for Q2 2025, and $2.9 million during Q1 2025.